NorthWest Biotherapeutics Inc (NWBO)

[jm100]

Dr. Zavoico earned his BS in Biology from St. Lawrence University in Canton, NY, and a Ph.D. in Physiology from the University of Virginia, Charlottesville, VA. He completed post-doctoral fellowships in Pharmacology at the University of Connecticut Health Center in Farmington, CT, and Hematology at Brigham & Women’s Hospital and Harvard Medical School, Boston, MA. At Bristol-Myers Squibb, Dr. Zavoico was involved in drug discovery research in thrombosis and then cell therapy and complement therapeutics development at Alexion Pharmaceuticals and T Cell Sciences. For several years, Dr. Zavoico served as a consultant in competitive intelligence, regulatory affairs, and medical writing for the biotech and pharmaceutical industries, which included Pfizer and Boehringer-Ingelheim as clients. He then transitioned to become a sell-side equity analyst for Cantor-Fitzgerald, MLV & Co., JonesTrading, and B. Riley FBR. In over 15 years he covered a broad range of small-to-mid size biotech and biopharmaceutical companies engaged in developing drugs and/or cell therapies for cancer, autoimmune diseases and inflammation, neurological and cardiovascular disorders, rare diseases, and vaccines. In the past several years, Dr. Zavoico returned to work in the biotech industry in investor relations and corporate development to first assist Cue Biopharma and now Northwest Biotherapeutics in developing their cancer immunotherapies. Dr.Zavoico has authored more than 30 scientific papers and book chapters and was the recipient of a Financial Times/Starmine Analyst award for two years in a row. He has collaborated with the NY Academy of Sciences for over 30 years in planning and organizing symposia on multiple topics, including the annual Frontiers of Cancer Immunotherapy symposium.